Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lb Pharmaceuticals (LBRX) Cash from Operations (2024 - 2026)

Lb Pharmaceuticals' quarterly Cash from Operations came in at 23290000.0 in Q1 2026, down 186.54% year-on-year from 26912300.26 in Q1 2025, and down 28.67% quarter-over-quarter from 18100000.0 in Q4 2025.

Lb Pharmaceuticals has reported Cash from Operations for 3 years, with the latest figure at 23290000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Operations fell 186.54% year-over-year to 23290000.0; the trailing twelve-month figure through Mar 2026 stood at 55183000.0 (changed N/A YoY), and the FY2025 full-year result was 35200000.0, up 33.65% from the prior year.
  • Cash from Operations for Q1 2026 stood at 23290000.0, down from 18100000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 5665000.0 in Q4 2024, with the low at 23290000.0 in Q1 2026.
  • Average Cash from Operations over 3 years is 13795750.0, with a median of 13114000.0 recorded in 2025.
  • Year-over-year, Cash from Operations sank 219.51% in 2025 and slumped 186.54% in 2026.
  • Tracing LBRX's Cash from Operations over 3 years: stood at 5665000.0 in 2024, then slumped by 219.51% to 18100000.0 in 2025, then retreated by 28.67% to 23290000.0 in 2026.
  • The last three Cash from Operations figures came in at 23290000.0 (Q1 2026), 18100000.0 (Q4 2025), and 8128000.0 (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -1.67 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 1.43 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 1.08 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 70.50 Mn
10 Lb Pharmaceuticals 789.92 Mn 789.92 Mn - -23.29 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -23.29 Mn
Mar 31, 2026 -23.29 Mn
Dec 31, 2025 -18.10 Mn
Dec 31, 2025 -18.10 Mn
Mar 31, 2025 -8.13 Mn
Mar 31, 2025 -8.13 Mn
Dec 31, 2024 -5.67 Mn
Dec 31, 2024 -5.67 Mn